CRLF2 and acute lymphoblastic leukemia: Recent studies suggest that patients with CRLF2 rearrangements exhibit resistance to glucocorticoids, a key component of ALL therapy, but this resistance can be overcome with MEK or Akt inhibition, presenting new avenues for targeted treatment [140].